APG Asset Management US Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 7,894 shares of the medical research company's stock, valued at approximately $4,107,000.
Several other institutional investors have also recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $3,149,754,000. Proficio Capital Partners LLC raised its holdings in Thermo Fisher Scientific by 68,617.0% in the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock valued at $396,810,000 after buying an additional 761,649 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $377,901,000. Grantham Mayo Van Otterloo & Co. LLC boosted its stake in shares of Thermo Fisher Scientific by 140.7% during the 4th quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 1,093,866 shares of the medical research company's stock valued at $569,062,000 after buying an additional 639,467 shares during the last quarter. Finally, Lindsell Train Ltd bought a new position in Thermo Fisher Scientific during the 4th quarter valued at $211,858,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Thermo Fisher Scientific
In other news, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. This represents a 26.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the firm's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now owns 10,816 shares of the company's stock, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is owned by company insiders.
Thermo Fisher Scientific Price Performance
Shares of Thermo Fisher Scientific stock traded up $6.14 during trading on Monday, hitting $444.29. The stock had a trading volume of 967,204 shares, compared to its average volume of 1,696,154. Thermo Fisher Scientific Inc. has a 12 month low of $409.85 and a 12 month high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market cap of $167.61 billion, a price-to-earnings ratio of 26.88, a P/E/G ratio of 2.99 and a beta of 0.86. The business's 50-day moving average is $510.56 and its 200 day moving average is $538.78.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.39%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, March 14th. Thermo Fisher Scientific's payout ratio is presently 10.41%.
Wall Street Analyst Weigh In
Several analysts recently weighed in on TMO shares. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Tuesday, January 14th. Morgan Stanley increased their price objective on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Royal Bank of Canada set a $693.00 price objective on Thermo Fisher Scientific in a research note on Friday, January 31st. Scotiabank boosted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the stock a "sector perform" rating in a research report on Monday, February 3rd. Finally, Raymond James reiterated an "outperform" rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $647.43.
Get Our Latest Stock Report on TMO
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Stories
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
